Allergic asthma is driven by type 2 immune cells including type 2 innate lymphoid cells (ILC2s). ILC2s respond to the tissue alarmins IL-33 and IL-25, however these signals do not uniquely promote type 2 inflammation, and the factors that maintain ILC2s ability to produce type 2 cytokines are not known. Here, we show that allergen-driven tissue alarmins IL-33 and IL-25 rapidly induce IL-9, which directly upregulates the transcriptional repressor Blimp-1 through an autocrine/paracrine mechanism. Blimp-1 promotes type 2 responses by directly repressing type 1 inflammation including the cytokines IFNγ and TNF. Deletion of Blimp-1 in ILC2s increases type 1 cytokines and concomitantly reduces type 2 cytokines, ameliorating mucus production and airway inflammation in response to allergens. Thus, Blimp-1 maintains the type 2 transcriptional identity of ILC2s in response to inflammation, driving type 2 immunity and allergic asthma.
https://doi.org/10.1038/s41590-026-02509-3
Related products
| Catalog No. | Product Name | Description | Target |
|---|---|---|---|
| HB771016 | Anti-Human IL-9 Reference Antibody (Enokizumab | Research Grade Enokizumab (HB771016) is a humanized monoclonal antibody detecting T-cell growth factor P40 in ELISA, Bioactivity: FACS, Functional assay, Research in vivo. Suitable for Human. Highlights ●Multi-Application — Validated across multiple applications. | T-cell growth factor P40, Cytokine P40, IL9, Interleukin-9, IL-9 |

24小时产品查询

扫一扫关注我们

专属渠道经理